Silexion Therapeutics Corp

Contributing Author

Recent Articles by Silexion Therapeutics Corp

Mar-24	Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer SLXN +5.51% GlobeNewswire
Mar-24	Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer SLXN +5.51% GlobeNewswire
Mar-17	Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update SLXN GlobeNewswire
Mar-05	Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting SLXN GlobeNewswire
Jan-21	Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit SLXN -5.80% GlobeNewswire
Jan-06	Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 SLXN GlobeNewswire
Dec-16	Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer SLXN GlobeNewswire
Dec-02	Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer SLXN -7.61% GlobeNewswire
Nov-26	Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference SLXN +20.42% GlobeNewswire
Nov-25	Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer SLXN +7.62% GlobeNewswire
Nov-12	Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update SLXN GlobeNewswire
Sep-30	Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer SLXN GlobeNewswire
Sep-25	Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements SLXN GlobeNewswire
Sep-11	Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering SLXN +9.92% GlobeNewswire
Sep-11	Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration SLXN +9.92% GlobeNewswire
Sep-04	Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 SLXN GlobeNewswire
Sep-02	Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference SLXN GlobeNewswire
Aug-12	Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update SLXN GlobeNewswire
Jul-31	Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds SLXN -37.88% GlobeNewswire
Jul-31	Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation SLXN +31.98% GlobeNewswire
Jul-16	Silexion Therapeutics Announces 1-for-15 Reverse Share Split SLXN -8.56% GlobeNewswire
Jul-09	Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines SLXN +12.33% GlobeNewswire
May-29	Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers SLXN GlobeNewswire
May-21	Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer SLXN GlobeNewswire
May-13	Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update SLXN GlobeNewswire

Silexion Therapeutics Corp

Recent Articles by Silexion Therapeutics Corp

Upgrade your FINVIZ experience